Skip to main content

Advertisement

SpringerLink
Log in

Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

The aim of this study was to evaluate the usefulness of high-dose 131I therapy administered only on the basis of raised serum Tg levels.

Methods

Among patients treated with total or near-total thyroidectomy and 131I ablation, 76 (54 women and 22 men) with differentiated thyroid cancer (41 with follicular and 35 with papillary cancer) showed a detectable (i.e. >1.5 ng/ml) serum Tg level on l-thyroxine therapy during follow-up and were included in the study. In these patients, a further 131I therapy was scheduled (range 3.7–9.25 GBq, mean 6.087±1.705). Five to seven days after this radioiodine therapy, patients underwent 131I post-therapy whole-body scan (131I t-WBS). The serum Tg value at 12 months after 131I therapy was evaluated as an indicator of short-term response to radioiodine.

Results

At evaluation after 12 months, 21 (27.6%) of the 76 patients had a Tg value ≤1.5 ng/ml, 12 (15.8%) showed a Tg decrease of at least 50%, 22 (29%) had only a minor decrease in Tg (<50%) and 21 (27.6%) did not show any decrease in Tg. 131I t-WBS was positive in 52 patients (68%, group A) and negative in 24 (32%, group B). Normalisation of Tg was observed in 15 patients (29%) of group A and in six patients (25%) of group B. Overall, 23 (44%) patients of group A and ten (42%) of group B showed a ≥50% decrease in the Tg. Of the 52 patients of group A, 19 (36%) had local recurrence at 131I t-WBS, 18 (35%) showed lung involvement and 15, (29%) bone metastasis. On a patient basis, two (13%) of 15 patients with bone metastases, six (33%) of 18 patients with lung involvement and seven (37%) of 19 patients with local recurrence had Tg values at follow-up of ≤1.5 ng/ml (p NS). Overall, seven (37%) patients with local recurrence, eight (44%) with lung involvement and eight (53%) with bone metastases showed a ≥50% decrease in Tg.

Conclusion

The findings of the present study suggest that the administration of therapeutic 131I only on the basis of elevated Tg levels has a definite therapeutic effect, at least in the short term. In addition, the possibility of obtaining a post-therapeutic 131I WBS can lead to better strategy definition for these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ozata M, Suzuki S, Myamoto T, Liu RT, Fierro-Renoy F, Degrot LJ. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994;79:98–105

    Article  PubMed  Google Scholar 

  2. Duren M, Siperstein AE, Sheen W, Duh QY, Morita E, Clark OH. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high and low-risk patients. Surgery 1999;126:13–9

    Article  PubMed  Google Scholar 

  3. Pacini F, Pinchera A. Serum and tissue thyroglobulin measurements: clinical applications in thyroid disease. Biochimie 1999;81:463–7

    Article  PubMed  Google Scholar 

  4. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433–41

    Article  PubMed  Google Scholar 

  5. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Tadei D, Pinchera A. Diagnostic 131-I whole body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002;87:1499–501

    Article  PubMed  Google Scholar 

  6. Lind P. I-131 whole body scintigraphy in thyroid cancer patients. Q J Nucl Med 1999;43:188–94

    PubMed  Google Scholar 

  7. Lind P. Should high hTg levels in the absence of iodine uptake be treated? For. Eur J Nucl Med Mol Imaging 2003;30:157–60

    Article  PubMed  Google Scholar 

  8. Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli JP, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986;63:960–7

    PubMed  Google Scholar 

  9. Nemec J, Rohling S, Zamrazil V, Pohunkova D. Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancer. J Nucl Med 1979;20:92–7

    PubMed  Google Scholar 

  10. Pacini F, Lari R, Mazzeo S, Grasso L, Taddei D, Pinchera A. Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer. Clin Endocrinol (Oxf) 1985;23:405–11

    Google Scholar 

  11. Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest x-ray. J Nucl Med 1988;29:1790–4

    PubMed  Google Scholar 

  12. Sherman SI, Tielens ET, Sostre S, Wharam MD Jr, Ladenson PW. Clinical utility of post treatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 1994;78:629–34

    Article  PubMed  Google Scholar 

  13. Reynolds JC. Percent 131-I uptake and post-therapy 131-I scans: their role in the management of thyroid cancer. Thyroid 1997;7:281–4

    PubMed  Google Scholar 

  14. Schlumberger M. Use of radioactive iodine in patients with papillary and follicular thyroid cancer: toward a selective approach. J Clin Endocrinol Metab 1988;83:4201–3

    Article  Google Scholar 

  15. Bierman M, Schober O. Should high hTg levels in the absence of iodine uptake be treated? Against. Eur J Nucl Med Mol Imaging 2003;30:160–3

    Article  PubMed  Google Scholar 

  16. Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic 131-I whole body scan: comparison of patients treated with high 131-I activities versus untreated patients. J Clin Endocrinol Metab 2001;86:4092–7

    Article  PubMed  Google Scholar 

  17. Fatourechi V, Hay ID, Javedan H, Wiseman GA, Mullan BP, Gorman CA. Lack of impact of radioiodine therapy in Tg positive, diagnostic whole body scan-negative patients with follicular cell-derived thyroid cancer. J Clin Endocrinol Metab 2002;87:1521–6

    Article  PubMed  Google Scholar 

  18. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995;80:1488–92

    Article  PubMed  Google Scholar 

  19. Koh JM, Kim Es, Ryu JS, Hong SJ, Kim WB, Shong YK. Effects of therapeutic doses of 131-I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131-I whole body scan: comparative study. Clin Endocrinol 2003;58:421–7

    Article  Google Scholar 

  20. Venkataraman GM, Yatin M, Ain KB. Cloning of the human sodium-iodine symporter promoter and characterization in a different human thyroid cell line. Thyroid 1998;8:63–9

    PubMed  Google Scholar 

  21. Lazar V, Bidart JM, Caillou B, Mahe C, Lacroix L, Filetti S, et al. Expression of the Na+7I—symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 1999;84:3228–34

    Article  PubMed  Google Scholar 

  22. Arturi F, Russo D, Schlumberger M, du Villard JA, Caillou B, Vigneri P, et al. Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab 1998;83:2493–6

    Article  PubMed  Google Scholar 

  23. Min JJ, Chung JK, Lee YJ, Jeong JM, Lee DS, Jang JJ, et al. Relationship between expression of the sodium/iodide symporter and 131-I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med 2001;28:639–45

    Article  PubMed  Google Scholar 

  24. Robbins RJ, Schlumberger MJ. The evolving role of 131-I for the treatment of differentiated thyroid carcinoma. J Nucl Med 2005;46:28S–37S

    PubMed  Google Scholar 

  25. Schmutzler C. Regulation of the sodium/iodide symporter by retinoids: a review. Exp Clin Endocrinol Diabetes 2001;109:41–4

    Article  PubMed  Google Scholar 

  26. Pacini F. Follow-up of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2002;20:S492–6

    Google Scholar 

  27. Stokkel MPM, Verkooijen RB, Smit JWA. Indium-111 octreotide scintigraphy for the detection of non-functioning metastasis from differentiated thyroid cancer: diagnostic and prognostic value. Eur J Nucl Med Mol Imaging 2004;31:950–7

    Article  PubMed  Google Scholar 

  28. Gabriel M, Froehlich F, Decristoforo C, Ensinger C, Donnemiller E, von Guggenberg E, et al. 99mTc-EDDA/HYNIC-TOC and 18F-FDG in thyroid cancer patients with negative 131I whole-body scans. Eur J Nucl Med Mol Imaging 2004;31:330–41

    Article  PubMed  Google Scholar 

  29. Hooft L, Hoekstra OS, Deville W, Lips P, Teule CJJ, Boers M, et al. Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:3779–86

    Article  PubMed  Google Scholar 

  30. Schluter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131-I scan. J Nucl Med 2001;42:71–6

    PubMed  Google Scholar 

  31. Helal BO, Merlot P, Toubert ME, Franc B, Schvartz C, Gauthier-Koelesnikov H, et al. Clinical impact of 18-F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative 131-I scanning results after therapy. J Nucl Med 2001;42:1464–9

    PubMed  Google Scholar 

  32. Alnafisi NS, Driedger AA, Coates G, Moote DJ, Raphael SJ. FDG PET of recurrent or metastatic 131-I-negative papillary thyroid carcinoma. J Nucl Med 2000;41:1010–5

    PubMed  Google Scholar 

  33. Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, et al. Prognostic value of (18F)fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000;85:1107–13

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Scienze Biomorfologiche e Funzionali, Università degli Studi di Napoli Federico II, Napoli, Italy

    Leonardo Pace, Michele Klain, Carmine Albanese, Barbara Salvatore & Marco Salvatore

  2. Istituto di Biostrutture e Bioimmagini, C.N.R., Napoli, Italy

    Leonardo Pace, Giovanni Storto & Marco Salvatore

  3. Università degli Studi Parthenope, Napoli, Italy

    Andrea Soricelli

Authors
  1. Leonardo Pace
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michele Klain
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carmine Albanese
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Barbara Salvatore
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giovanni Storto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andrea Soricelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marco Salvatore
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leonardo Pace.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pace, L., Klain, M., Albanese, C. et al. Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment. Eur J Nucl Med Mol Imaging 33, 179–183 (2006). https://doi.org/10.1007/s00259-005-1929-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-005-1929-2

Keywords

Search

Navigation